Background: Dengue is the most serious arboviral illness in humans. Over the past few decades, there has been a significant increase in the prevalence of dengue fever (DF) and dengue hemorrhagic fever (DHF) worldwide. The present study evaluated hepatic manifestations in dengue fever and their correlation with severity of dengue fever. Materials & Methods: 76 cases of dengue fever of both genders were selected. Hemoglobin, hematocrit, platelet count, total and differential leukocyte count, liver function tests, and urine analysis were among the parameters evaluated. Results: Out of 76 patients, 40 were males and 36 were females. Common symptoms in patients with DF, DHF I, DHF II, DHF III and DHF IV was headache was seen in 12, 7, 11, 18 and 8 respectively. Body pain was seen in 8, 6, 8, 14 and 7, vomiting in 5, 4, 7, 11 and 4, retro-orbital pain in 9, 3, 6, 17 and 3 patients respectively. Jaundice in 6, 8, 5, 19 and 5 patients respectively. The difference was significant (P< 0.05).AST (SGOT) >50 IU/L was seen in 9, 6, 12, 4 and 7 patients. ALT (SGPT) >50 IU/L in 11, 5, 13, 6 and 8. S. Alkaline P. >200 IU/L in 3, 4, 6, 5 and 1 patient. The mean hemoglobin level was 10.1, 10.4, 11.5, 10.6 and 10.8. Haematocrit was 32.4, 31.2, 32.6, 32.0 and 32.8. Bilirubin was 0.61, 0.54, 0.67, 0.75 and 0.78 in DF, DHF I, DHF II, DHF III and DHF IV, respectively. The difference was significant (P< 0.05). Conclusion: Epidemics of dengue are occurring more frequently. Different levels of hepatic involvement have been reported. Since dengue is a transient and curable illness, early diagnosis of hepatic impairment could help avoid potentially catastrophic outcomes.